Novel antimircrobial and biofilm resistant coatings for urological and blood storage devices

用于泌尿科和血液储存设备的新型抗菌和抗生物膜涂层

• 批准号: 414197-2012
• 负责人: Kizhakkedathu, Jayachandran
• 金额: $ 15.98万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=530857
• 关键词: Novel; antimircrobial; biofilm; resistant; coatings

This research addresses serious challenge in hospital acquired infections: the prevention of bacterial infections associated with urological devices and bacterial growth in blood products for transfusion. Urinary catheters is one of most frequently used medical device in hospitals in North America and catheter associated infections account for a major share of hospital acquired infectious. In addition to increased mortality, these complications add millions of extra health care costs. Currently, antibiotics are our only method of attempting to deal with these infections, but do not work well due to intrinsic multidrug resistance of biofilms on catheter surface. The transfusion of bacterial contaminated blood products is another longstanding serious complication. In North America, approximately 15 million units of packed red blood cells and 4.5 million units of platelets are transfused every year. The incidence of bacterial contamination associated with the storage is as high as 1

本研究解决了医院获得性感染的严重挑战：预防与泌尿系统器械相关的细菌感染和输血用血液制品中的细菌生长。导尿管是北美医院最常用的医疗器械之一，导管相关感染占医院获得性感染的主要份额。除了增加死亡率外，这些并发症还增加了数百万的额外医疗保健费用。目前，抗生素是我们试图处理这些感染的唯一方法，但由于导管表面生物膜的内在多药耐药性，效果不佳。输注被细菌污染的血液制品是另一个长期存在的严重并发症。在北美，每年约输注1500万单位的浓缩红细胞和450万单位的血小板。与储存相关的细菌污染发生率高达1